ALEC Alector Inc

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will present at the following upcoming investor conferences:

• Barclays Global Healthcare Conference (Miami, Florida)
  • Wednesday, March 16, 2022 at 3:20 p.m. ET, Fireside Chat
• Stifel CNS Days (Virtual)
  • Monday, March 28, 2022 at 11:30 a.m. ET, Corporate Presentation

Live webcasts of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About AlectorAlector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Contacts:

1AB (media)Dan Budwick973-271-6085dan@1abmedia.com

Argot Partners (investors)Eric Kasper/Carrie McKimArgot Partners212.600.1902alector@argotpartners.com